Business
First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial
Enrollment remains on track with internal interim results expected in Q2 2026Randomized study to evaluate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging bi
About this update from Aclarion, Inc.
[{"type":"image","alt":"Aclarion, Inc.","displaySize":"","headline":null,"caption":"Aclarion, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":140,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/ba6de721dd8ef6e3bce232e051476ebf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JqjNbxSKpdl2ksI_nXtiLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ba6de721dd8ef6e3bce232e051476ebf","width":140,"height":83}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Enrollment remains on track with internal interim results expected in Q2 2026","length":77,"tagName":"p"}]},{"val":[{"type":"text","content":"Randomized study to evaluate Nociscan’s ability to improve surgical outcomes for chronic low back pain ","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)","length":143,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":322,"olType":false},{"type":"text","content":"BROOMFIELD, Colo., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that the UHealth – University of Miami Health System and the Miller School of Medicine enrolled its first two patients in the CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial. The pivotal CLARITY study is designed to demonstrate Nociscan’s clinical and economic value in spine surgery.","length":652,"tagName":"p"},{"type":"text","content":"“We are pleased to have enrolled our initial patients at the University of Miami Health System,” commented Gregory Basil, M.D., Director of Endoscopic Spine Surgery and Assistant Professor at UHealth and the Miller School. “CLARITY is an important trial for spine surgeons and their patients with low back pain. The additional information provided by Nociscan is challenging pre-conceived notions about the sources of low back pain and we look forward to understanding the correlation between surgical outcomes and the patient-specific...